CONNECT BIOPHARMACEUTICALS
Connect Biopharmaceuticals is a clinical-stage company that discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. They identify and advance our drug candidates through in-house discovery and in-licensing while leveraging qualified CROs for further development. The company successfully completed a phase I clinical trial study on our leading program CBP-307, a novel and selective second-generation S1P1 (a G-protein coupled receptor -GPCR) modulator for t... he treatment of a range of autoimmune disorders, including multiple sclerosis, inflammatory bowel disease, and psoriasis. Connect Biopharmaceuticals currently conducting two phases 2 clinical studies in patients with ulcerative colitis and Crohn's disease with their lead drug candidate CBP-307. It also concluding a phase 1 study of our second drug candidate CBP-201 in healthy subjects, with a phase 1b study in atopic dermatitis patients expected to commence in Q1, 2019. Connect Biopharmaceuticals was founded in 2012 and is headquartered in Taichang, China.
CONNECT BIOPHARMACEUTICALS
Industry:
Biotechnology Clinical Trials Health Care Medical Therapeutics
Founded:
2012-01-01
Address:
Taicang, Hebei, China
Country:
China
Website Url:
http://www.connectbiopharm.com
Total Employee:
1+
Status:
Active
Contact:
0512-53577866
Email Addresses:
[email protected]
Total Funding:
195 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Asahi Genomics
Asahi Genomics is into development of clinical testing technology, business related to overcoming diseases and improving / promoting health.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Qiming Venture Partners
Qiming Venture Partners investment in Series C - Connect Biopharmaceuticals
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - Connect Biopharmaceuticals
RA Capital Management
RA Capital Management investment in Series C - Connect Biopharmaceuticals
Boxer Capital
Boxer Capital investment in Series C - Connect Biopharmaceuticals
Lilly Asia Ventures
Lilly Asia Ventures investment in Series C - Connect Biopharmaceuticals
Northern Light Venture Capital
Northern Light Venture Capital investment in Series B - Connect Biopharmaceuticals
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Connect Biopharmaceuticals
Cowin Capital
Cowin Capital investment in Series B - Connect Biopharmaceuticals
Advantech Capital
Advantech Capital investment in Series B - Connect Biopharmaceuticals
Cowin Capital
Cowin Capital investment in Series A - Connect Biopharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-22 | Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer |
Official Site Inspections
http://www.connectbiopharm.com Semrush global rank: 4.88 M Semrush visits lastest month: 1.8 K
- Host name: 44.153.244.35.bc.googleusercontent.com
- IP address: 35.244.153.44
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Connect Biopharmaceuticals"
About Us - Connect Biopharm
Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research.See details»
Connect Biopharm - Next-Generation Therapeutics for T Cell โฆ
CBP-201, an anti-IL-4Ra antibody, is in clinical trial development to treat atopic dermatitis (AD) patients with moderate-to-severe AD. A Phase 2b study in this population showed CBP-201 โฆSee details»
Senior Management Team - Connect Biopharm
Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies โฆSee details»
Press Release - Connect Biopharma Holdings Ltd
Mar 1, 2022 โWe are delighted to welcome Dr. Lee to Connectโs executive team at a pivotal time for the organization,โ said Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma. ...See details»
Connect Biopharmaceuticals - Crunchbase Company Profile
Connect Biopharmaceuticals may be growing as evidenced by a significant licensing deal where Suzhou Connect Biopharmaceuticals Ltd. licensed the China rights to rademikibart (CBP-201) โฆSee details»
Connect Biopharma Announces New Leadership and Chair of the โฆ
Jun 12, 2024 Connect Biopharma Holdings Limited. Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the โฆSee details»
| Connect Biopharma Holdings Ltd
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of โฆSee details»
Investors - Connect Biopharma Holdings Ltd
Sep 10, 2024 The Investor Relations website contains information about Connect Biopharma Holdings Ltd's business for stockholders, potential investors, and financial analysts.See details»
Scientific Advisory Board - Connect Biopharm
In 2014, Dr. Guttman-Yassky co-founded the International Eczema Council, an organization that includes more than 100 of the worldโs leaders in eczema, and currently serves as its president. โฆSee details»
Connect Biopharma Announces Positive Rademikibart Global โฆ
Strong and significant improvement in asthma control was also observed. The absolute placebo-adjusted changes from baseline in the Asthma Control Questionnaire (ACQ) score at Week 24 โฆSee details»
Press Release - Connect Biopharma Holdings Ltd
Mar 31, 2022 - Global Phase 3 Trial of CBP-201 in Moderate-to-Severe Atopic Dermatitis Expected to Commence in H2 2022 - - Topline Phase 2 CBP-307 Results in Moderate-to โฆSee details»
ๅบทไนๅพท - connectbiopharm.com.cn
For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com. IR/PR CONTACTS: Lazar FINN Partners David Carey (IR) T: +1 โฆSee details»
Connect Biopharma Establishes Scientific Advisory Board โฆ
Jan 5, 2021 SAN DIEGO and TAICANG, SUZHOU, China, Jan. 5, 2021 /CNW/ -- Connect Biopharma, a global clinical-stage biopharmaceutical company focused on the discovery and โฆSee details»
Pipeline - Connect Biopharm
Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies โฆSee details»
PRESS RELEASES - Connect Biopharm
SAN DIEGO, CA and TAICANG, SUZHOU, China โ October 29, 2020 โ Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next โฆSee details»
Connect Biopharma to Participate at Upcoming Conferences
Nov 11, 2021 For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com. IR/PR CONTACTS: Lazar FINN Partners David Carey (IR) T: +1 โฆSee details»
Connect Biopharma Strengthens Leadership Team with Key Hire
Jan 26, 2021 /CNW/ -- Connect Biopharma, a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases...See details»
Clinical Trials - Connect Biopharm
Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies โฆSee details»
Complete Data from Connect Biopharma's Phase 1b Study of CBP โฆ
Oct 29, 2020 Complete Data from Connect Biopharma's Phase 1b Study of CBP-201 Demonstrate Rapid, Early and Continuous Improvement in Patient Quality of Life and Atopic โฆSee details»
Careers - Connect Biopharm
We begin with a clear goal in mind, to improve the lives of patients living with chronic inflammatory diseases. We believe that by leveraging our core expertise in T cell-driven research and our โฆSee details»